Obesity White Papers & Case Studies

  1. Building A Scalable Oncology Engine In A Dynamic Market 6/3/2026

    Learn how a top-10 global pharmaceutical company partnered with Medable to rapidly scale the number of oncology trials it could concurrently conduct.

  2. Meeting The FDA's New Real-World Evidence Standards 5/27/2026

    FDA guidance is reshaping RWE strategy. Sponsors that build interoperable, audit-ready RWD infrastructure now will be best positioned for faster, defensible submissions.

  3. The eCOA Iceberg 5/27/2026

    Understand the true cost of eCOA deployment, beyond software licenses, to reduce protocol risk, avoid operational bottlenecks, and protect study timelines and data quality.

  4. ICH E6(R3) Is Here: How Should You Handle It? 5/27/2026

    Prepare for ICH E6(R3) with integrated oversight, audit-ready data, and streamlined trial operations designed to reduce burden, accelerate timelines, and support compliance.

  5. Navigating The Challenges Of Large, International Phase III Breast Cancer Trials 5/27/2026

    In the competitive landscape of breast cancer research, aligning biomarker testing, regulatory pathways, and regional operations from day one creates a path to faster enrollment and stronger outcomes.

  6. Data Management Without The Coordination Friction 5/27/2026

    Simplify clinical data management with one connected platform and an expert team delivering faster study startup, cleaner data, fixed-fee predictability, and fewer operational delays.

  7. De-Risking The Neurology IND: Lessons From Early FDA Engagement 5/27/2026

    Learn how early FDA alignment can help your neurology program move forward with greater clarity, confidence, and regulatory readiness.

  8. Successful EU MAA Submission Enabled By U.S.–EU Regulatory Collaboration 5/27/2026

    Facing EU MAA complexity? Learn how one oncology sponsor met a fixed EMA deadline through global regulatory coordination, rapid dossier adaptation, and real-time submission execution.

  9. Relieving Pressure During Preparation Of A High-Volume sNDA 5/27/2026

    Managing a complex sNDA under pressure? See how one sponsor achieved an early FDA submission through coordinated publishing, regulatory strategy, and flawless execution.

  10. Supporting Global Approval Of A First-In-Class Gene Therapy For A Rare Genetic Disorder 5/27/2026

    Global approvals for a first-in-class gene therapy don’t happen by chance. See how adaptive oversight and inspection readiness kept a complex rare disease program moving forward.